# Aurinia Pharmaceuticals Inc. (AUPH)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001600620 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001600620))
- Full page: https://inspectstocks.com/stocks/auph
- Data as of: price 2026-09-25; newest filing used 2026-08-06; latest fiscal period ended 2026-06-30

## Grade

**A+** on the balance-sheet rubric used for lenders, 5 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | $314.1M |  |
| Earnings growing overall | passed | $314.1M | -$72.7M |
| Earnings growing recently | passed | $314.1M | $287.2M |
| Earns well on its assets | passed | 39.6% |  |
| Book value per share growing | passed | $4.19 | $2.86 |

Business quality (the + / − mark): 5 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 100.8% |  |
| Healthy profit margin | passed | 100.8% |  |
| Strong operating margin | passed | 48.4% |  |
| Good return on equity | passed | 54.0% |  |
| Debt under control | passed | 0.13 |  |
| Turns sales into cash | failed | -20.4% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $311.5M |
| Net income, trailing twelve months | $314.1M |
| Net margin | 100.8% |
| Operating margin | 48.4% |
| Return on equity | 54.0% |
| Debt to equity | 0.13 |
| Diluted EPS, trailing twelve months | $2.29 |
| Share price | $16.44 |
| Market value | $2.2B |
| Price / earnings | 7.2x |
| Price / sales | 7.0x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/auph)
- [Financial statements](https://inspectstocks.com/stocks/auph/financials)
- [Competitors](https://inspectstocks.com/stocks/auph/peers)
- [Earnings](https://inspectstocks.com/stocks/auph/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.